Guest guest Posted April 2, 2009 Report Share Posted April 2, 2009 HI GANG, Per conversation on the chat, here is the info on the trial drug. ARTEMIS: a phase 3, randomized, double-blind, placebo controlled, multi-center, parallel group, event driven study to evaluate the efficacy and safety of Ambrisentan in subjects with early Idiopathic Pulmonary Fibrosis (IPF). The company sponsoring is Gilead Sciences Inc. They are located in Seattle, Washington Protocol no: GS-US-231-0101 WRIB Protocol #20081290 W00000067 The study is 1-3 years. I was informed the study will begin in the next 4-6 weeks. I will receive a call next week to fill me in on schedule. As I learn more I will keep ya'll informed. I enjoyed chat tonight. It is nice to hear voices of fellow comrades with this stupid disease. Hope all is well, Joe JOE & JOANIE LAMENSKIE IPF JAN. 2008 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.